Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy by Huisman, C et al.
For patients with advanced non-small-cell lung cancer (NSCLC)
treatment with chemotherapy results in symptom improvement
and a small but significant survival benefit (Non-small cell lung
cancer collaborative group, 1995). Cisplatin was an essential part
of the combinations used and the other necessary drugs to achieve
these effects were not identified. Therefore, cisplatin-containing
combinations are currently considered the optimal treatment for
advanced NSCLC patients with a good performance score (ASCO
guidelines, 1997). Yet these regimens remain unsatisfactory
because of treatment-related morbidity and limited effect on
survival (Crinò et al, 1997). To improve upon these results, new
drugs and new combinations are being extensively investigated in
NSCLC. Given the short duration of response to first-line
chemotherapeutic treatment, there is a need for non-cross-resistant
chemotherapy in relapsing patients. Relapsing patients with a
good performance score are candidates for clinical trials with
novel agents or novel approaches, like dose-intensification
(Huisman et al, 2000). The combination of cisplatin and epirubicin
seems an attractive regimen to be explored for a dose–response
relationship. For anthracyclines, a number of cancer models and
phase I/II trials are indicative of such a relationship (Smit et al, 1992).
4″ -epidoxorubicin (epirubicin) is a less cardiotoxic synthetic
analogue of doxorubicin. When administered at doses up to 90 mg
m–2, single-agent epirubicin is not active in NSCLC (Kalman et al,
1983; Joss et al, 1984; Martoni et al, 1984; Meyers et al, 1986). In
contrast, high-dose epirubicin (120–150 mg m–2 every 4 weeks)
resulted in response rates ranging from 19–36% in chemotherapy-
naive patients with advanced NSCLC (Wils et al, 1990; Feld et al,
1992; Smit et al, 1992). Dose-limiting toxicity (DLT) is leukocy-
topenia of short duration, which may be overcome by the addition
of haematopoietic growth factors. 
The antitumour activity of single-agent high-dose epirubicin
stimulated interest in further evaluation of this compound in
combination with relatively non-myelosuppressive agents such as
cisplatin. Dose intensification with the aid of haematopoietic
growth factors was shown to be feasible for epirubicin single-
agent therapy (Fountzilas et al, 1994) as well as in combination
with paclitaxel (Lalisang et al, 2000) in breast cancer patients. In
small-cell lung cancer patients the combination of cisplatin(100 mg
m–2) plus escalating doses of epirubicin (100–150 mg m–2) was eval-
uated with the addition of granulocyte-macrophage colony-stimu-
lating factor in case severe neutropenia was encountered (Rossel
et al, 1994). The authors concluded that GM-CSF 250 µ gm –2 on
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7–12 consecutive days did not have a myeloprotective effect when
epirubicin was increased beyond 120 mg m–2. 
High-dose epirubicin in combination with cisplatin has been
tested as first-line treatment in NSCLC patients. In a direct
comparison high-dose epirubicin plus cisplatin was found to yield
similar therapeutic results as cisplatin-vinorelbine (Martoni et al,
1998). In the second-line setting, standard dose epirubicin (60
mg m–2) plus cisplatin (70 mg m–2) was reported to obtain a 25%
response rate in a group of 28 patients (Gridelli et al, 1992). All
were pretreated with a non-platinum-based regimen and 64% had
ECOG performance status 2. 
Here we report on the results of dose-intensification of the
cisplatin-epirubicin combination in patients with relapsed
NSCLC. On the basis of a previous study (Smit et al, 1992) we
considered the effective dose of epirubicin against NSCLC to be
135 mg m–2. We tested whether epirubicin 135 mg m–2 could be
combined with cisplatin and accelerated by G-CSF support.
Subsequently, the efficacy of this regimen was tested in patients
with relapsed NSCLC. 
PATIENTS AND METHODS 
Patients 
Patients with histologically or cytologically documented NSCLC
were eligible for this study. Entry criteria included age range 18 to
76 years, WHO performance status 0–2 and a life expectancy of at
least 2 months. Adequate haematological, renal and liver functions
were required, defined as WBC ≥ 3.0 × 109 l–1, platelets ≥ 100 ×
109 l–1, serum creatinine < 140 µ mol l–1 and/or creatinine clearance
>6 0m lm i n –1 (Cockroft–Gault formula) and bilirubin < 35 µ mol
l–1. Prior cytotoxic treatment and radiotherapy were allowed
provided that this had ended more than 4 weeks before entry into
this study. Prior treatment with anthracyclines should not exceed a
cumulative dose of 200 mg m–2 in case of doxorubicin and 650 mg
m–2 in case of epirubicin. In the phase II study, patients with
relapsed NSCLC after or progressive on previous chemothera-
peutic treatment were included and patients were required to have
bidimensionally measurable disease. Patients with symptomatic
brain metastases, signs of cardiac failure or an active infection
were excluded. Staging procedures consisted of chest X-ray and
chest–abdomen CT scan. Brain CT, bone scan and abdominal
ultrasound were performed when clinically indicated. The study
was approved by the medical ethical committee at the Vrije
Universiteit Amsterdam and all patients gave informed consent. 
Treatment 
Cisplatin (Brystol–Myers Squibb, Woerden, the Netherlands) was
diluted in 250 ml normal saline and administered intravenously
over 60 minutes on day 1 of each course. Epirubicin (Pharmacia &
Upjohn, Woerden, the Netherlands) dissolved in 250 ml normal
saline was infused over 30 minutes on day 1 of each cycle prior
to cisplatin. Forced intravenous hydration was administered with
cisplatin. Prophylactic parenteral antiemetics consisted of dexam-
ethasone plus a 5-HT3 receptor antagonist. A maximum of 6 cycles
was planned. The dose of cisplatin was fixed throughout the study at
60 mg m–2. The pre-defined dose levels of epirubicin in the phase I
study are shown in Table 1. Dose-escalation of epirubicin was
planned for, provided that none of the patients encountered DLT,
defined as haematological toxicity WHO grade IV lasting for more
than 5 days, neutropenic fever or any other toxicity exceeding WHO
grade III except alopecia during the first course. G-CSF (Filgastrim,
Amgen, Breda, the Netherlands) doses were 300 µ g day–1for patients
with a body weight < 60 kg and 480 µ g day–1 for patients with body
weight > 60 kg administered on days 3–12 as a subcutaneous injec-
tion. At each dose level 6 patients were to be enrolled. We investi-
gated whether epirubicin 135 mg m–2 could be combined with
cisplatin and accelerated by G-CSF support. 
Dose modification 
The chemotherapy cycle was to be postponed for 1 week and a
maximum of 2 weeks if WBC were < 3.0 × 109 l–1 and/or platelets
< 100 × 109 l–1 at scheduled retreatment. Patients went off treat-
ment if bone marrow recovery was still insufficient after 2 weeks
of postponement. 
Cisplatin was discontinued in case of creatinine clearance
<6 0m lm i n –1, oto-/neurotoxicity > WHO grade II. The dose of
epirubicin was to be decreased from 120 mg m–2 to 100 mg m–2
and from 135 mg m–2 to 120 mg m–2 in case DLT was encountered.
Epirubicin was discontinued if a second dose reduction of
epirubicin was necessary. 
Treatment evaluation 
Response to therapy was assessed every 2 courses according to WHO
criteria. Responses were analysed on an intention-to-treat basis. 
Toxicity was documented according to the WHO grading
system. Patients were evaluable for toxicity if at least 1 cycle was
completed. Investigations at entry consisted of medical history,
physical examination including neurologic evaluation, WHO
performance status, laboratory assessments (full blood count, elec-
trolytes, liver enzymes, bilirubin, creatinine, creatinine clearance,
total protein, albumin), electrocardiogram, tone and speech audio-
gram and tumour assessment (chest CT scan or other investiga-
tions that best defined disease extent and response evaluation).
During treatment, a full blood count was measured at least weekly.
Renal and liver function were determined before each cycle of
chemotherapy. An audiogram was repeated every second cycle. 
RESULTS 
Feasibility study 
From March 1997 to December 1997, 27 patients (22 men; median
age 61 years; 85% ECOG 0 – 1) were enrolled at 4 dose levels in
the initial feasibility study. 2 patients had stage IIIA disease, 11
stage IIIB and 14 stage IV. 14 patients had received previous
therapy for NCSLC, consisting of chemotherapy in 12 patients
(platinum-based in 2 patients), radiotherapy in 1 and combined
radio-chemotherapy in 1 patient. None of the patients had received
previous anthracyclines. 
A total of 86 courses were administered. The relative dose
intensity (RDI) of epirubicin was 0.98 (range 0.9–1) on dose level
1, 0.98 (range 0.91–1) on dose level 2, 0.98 (range 0.94–1) on dose
level 3 and 0.94 (range 0.83–1) on dose level 4. For cisplatin these
figures were 0.94 (range 0.6–1), 0.93 (range 0.6–1), 0.75 (range
0.2–1) and 0.94 (range 0.83–1), respectively. 
All patients were evaluable for toxicity. Haematological toxicity
was the principal side effect observed (Table 1). Anaemia led to
red blood cell transfusions in 19 patients. The median number of1458 C Huisman et al 
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transfusion units was 2 per patient. The percentage of patients
experiencing leukocytopenia WHO grade 3 or 4 at some time
during treatment was 88% on dose level 1, 83% on dose level 2,
67% on dose level 3 and 57% on dose level, 4. Infectious compli-
cations were encountered in 9 patients, including 3 cases of febrile
neutropenia (1 patient on dose level 1 after the second course, 2
patients on dose level 4 both after the third course). All patients
recovered uneventfully from these infectious complications.
Thrombocytopenia WHO grade 3 or 4 was noted in 38%, 50%,
17% and 43%, respectively. 1 patient on dose level 4 received a
platelet transfusion. No haemorrhagic event due to thrombocy-
topenia occurred, however. 
Non-haematological toxicity mainly consisted of nausea and
vomiting, grade 1 or 2 in 24 out of 27 patients. All evaluable
patients had alopecia ≥ WHO grade III. Grade I neurotoxicity
occurred in 1 patient and in 2 patients audiometry showed asymp-
tomatic hearing loss. In 5 patients creatinine clearance fell below
60 ml min–1 resulting in cisplatin discontinuation. One of these
patients was pretreated with cisplatin. Hypomagnesaemia ≥ WHO
grade II was observed in 37% of patients. 
Left ventricular ejection fraction was not assessed on a 
routine basis. In none of the patients were clinical manifestations
of congestive heart failure (CHF) observed during treatment.
However, 2 patients developed symptomatic cardiomyopathy at a
later stage. 1 patient had received a cumulative epirubicin dose of
270 mg m–2, followed by a total dose of 4000 cGy chest radio-
therapy. 4 weeks thereafter the patient developed signs of CHF that
favourably responded to cardiac medication. The other patient’s
medical history included general atherosclerosis and he had
received a cumulative epirubicin dose of 675 mg m–2. 6 weeks
after the last epirubicin dose he was admitted because of dyspnoea
due to severe left and right ventricular dysfunction. In spite of
treatment the cardiac impairment proved irreversible and the
patient died of CHF. 
2 patients died during the study because of tumour progression.
1 patient treated on dose level one had disease progression after
the first chemotherapy cycle and died because of acute renal
failure. 7 patients did not have evaluable disease or treatment was
stopped at their request after 1 course. 5 partial responses were
achieved and 10 patients had disease stabilization. No complete
responses were seen. Median survival time for all patients was 25
weeks (range 2–157 weeks). 
None of the patients encountered DLT in the first course, which
confirmed that epirubicin 135 mg m–2 could be combined with
cisplatin and accelerated by G-CSF support. Therefore, we
proceeded with a phase II study to evaluate cisplatin 60 mg m–2
and epirubicin 135 mg m–2 plus G-CSF support in a 14-day
schedule. 
Phase II study 
Patient characteristics 
A total of 27 patients (18 male, 9 female) with a median age of 50
years (range: 36–75) were included between October 1997 and
June 2000. 2 patients had stage IIIA disease, 8 stage IIIB and 17
stage IV. ECOG performance score was 0 in 11, 1 in 14 and 2 
in 2 patients. 14 patients had adenocarcinoma. All patients had
received prior chemotherapy for NSCLC, consisting of one
cisplatin-based regimen in 59% of patients. 2 patients had received
2 prior chemotherapy regimens: pretreatment consisted of one
platinum-based regimen in the 1 patient, whereas the other patient
had not received any previous cisplatin at all. 14 out of 27 patients
were considered as refractory, defined as relapsing within 3
months after or progressive on chemotherapy. The median time
between last chemotherapy and entry into the study was 3 months
(range 1–12 months). 6 patients had received radiotherapy on the
primary tumour and 2 patients on supraclavicular lymphnodes. 
2 patients had prior surgery. 
Treatment administration 
A total of 89 courses were administered. The median number of
courses administered to each patient was 3 (range 1 to 7). 1 patient
received 6 courses of single-agent epirubicin because of impaired
renal function after one course of cisplatin and epirubicin. 30% of
patients received only one course. 1-week postponement of the
next chemotherapy cycle due to thrombocytopenia occurred in
18% of courses. 2 patients went off study because of insufficient
bone marrow recovery after 2 weeks treatment delay. 
The relative dose intensity was 0.90 (range 0.1 to 1.00) for
cisplatin and 0.91 for epirubicin (range 0.69 to 1.00). In 4 cases
chemotherapy was stopped at the patient’s request. 2 patients died
during treatment due to progressive disease. One other early death
occurred in a patient who was admitted because of pneumonia.
The cause of death could not established since autopsy was not
performed in this unexpected case. 2 treatment-related deaths
occurred. 
Response and survival 
In 6 patients treatment was discontinued before evaluation of
response was performed: 3 patients died after the first cycle
because of progressive disease and 3 patients received only one
cycle at their own request. On an intention-to-treat basis 9 partial
responses and no complete responses were recorded in 27 patients
(33%; 95% confidence interval, 15–51%). 33% of patients had
disease stabilization. Response was not evaluable in 6 patients. 
5 out of 9 patients with partial responses had received prior 
platinum-containing therapy. 6 responders were considered 
Table 1 Dose levels and WHO haematologic toxicity (no. of patients) in the feasibility study 
Haemoglobin WBC  Platelets   
Cisplatin Epirubicin  q  G-CSF
Parameter Parameter  Parameter 
(mg m–2)( m g m – 2) (weeks) (5 µ gk g – 1 day–1)
(WHO grade) (WHO grade)  (WHO grade)
0–23 4  0 –23 4 0 –23 4  
Dose level 1 (n = 8) 60 120 3  – 62 0 1 3 4  5 3 0  
Dose level 2 (n = 6) 60 135 3  – 42 0 1 3 2 3  2 1  
Dose level 3 (n = 6) 60 135 3  + 6 0 0 2 3 1 5  0 1 
Dose level 4 (n = 7) 60 135 2  + 5 2 0 3 2 2  4 1 2 
Total (n = 27) 21 6 0 7 11 9 17 6 4 refractory to first-line treatment, defined as relapsing within 3
months after or progressive on chemotherapy. 
Median follow-up was 22 weeks. One patient was lost to
follow-up. The median duration of response was 28 weeks (range
6–55 weeks). At the time of analysis 6 patients were still alive.
Median survival time for all patients was 27 weeks (range 1–65
weeks). 
Toxicity 
All patients were evaluable for toxicity. Haematological toxicity
was the principal side effect (Table 2). 2 patients were not evalu-
able for anaemia because of concomitant use of erythropoietin.
20% of patients experienced grade III anaemia and 20 patients
received red blood cell transfusions. The median number of trans-
fusion units was 3 per patient. 70% and 63% of patients experi-
enced grade III or IV leukocytopenia and thrombocytopenia,
respectively. Platelet transfusions were necessary in 6 patients, 1
of whom experienced epistaxis and 1 had haemorrhagic discharge
from his tracheostoma. Infectious episodes occurred in 3 patients.
Moreover, 6 cases of febrile neutropenia were observed in 6
patients. Whereas 4 patients with febrile neutropenia recovered
uneventfully with intravenous antibiotics, 2 patients with febrile
neutropenia in their first course developed sepsis and died in spite
of antibiotic treatment. 
Non-haematological toxicity (Table 3) consisted mainly of
nausea and vomiting, which was severe (grade III) in 22% of
patients. Alopecia was universal. Renal toxicity grade I and II
occurred in 37% and 4% of patients, respectively. 55% of these
patients had received prior cisplatin-containing chemotherapy.
Hyponatriemia occurred in 2 patients and was symptomatic in 1 of
them. This patient had previously been treated with platinum.
Asymptomatic hypomagnesaemia ≥ WHO grade II was observed
in 50% of patients. No cardiac complications were observed
during the study. 
DISCUSSION 
This study was aimed to assess the feasibility and efficacy of high-
dose epirubicin in combination with cisplatin in patients with
advanced NSCLC who relapsed after or progressed on first-line
chemotherapy. The results of our initial feasibility study demon-
strated that epirubicin doses could be escalated to 135 mg m–2
every 2 weeks provided that G-CSF support was added. Further
dose escalation was not performed, since it has been reported that
treatment becomes more toxic and impracticable at doses of 150
mg m–2 or above (Martoni et al, 1991). 
Although chemotherapy is an established treatment for
advanced NSCLC, data on its therapeutic activity in relapsed
NSCLC are still very limited. Response rates in relapsed NSCLC
are poor and the first agent that has been approved for this indication
in several countries, docetaxel, obtained a response rate of 7–11%
in randomized trials (Fosella et al, 2000; Shepherd et al, 2000).
Against this background, our study of accelerated cisplatin and
high-dose epirubicin with G-CSF support suggests relevant
activity of this regimen in relapsed NSCLC. 
Criteria for the selection of patients for second-line
chemotherapy in NSCLC have not been clearly defined yet. The
need for definitions of patient groups is underlined by the upcoming
difficulty to test new drugs in previously untreated patients. The
second-line setting may be most suitable for testing new drugs or
drug combinations (Huisman et al, 2000). However, haematological
toxicities may be more pronounced in this patient population. 
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Table 2 Phase II: WHO haematologic toxicity (no. of patients) 
Worst WHO grade 
01 2 3 4
Parameter No. %  No. % No. % No. %  No. %
Haemoglobin 0 0 5 20 15 60 5 20 0 0 
WBC 1 4 5 19 2 7 6 22 13 48 
Platelets 0 0 7 26 3 11 7 26 10 37 
Table 3 Phase II: WHO nonhaematologic toxicity (no. of patients) 
Worst WHO grade 
01 234  
Parameter No. % No. % No. % No. % No. % 
Nausea/vomiting 3 11 12 44 6 22 6 22 0 0 
Hepatic 
Alkaline phosphatase 22 82 5 18  0 0 0 0 0 0 
Transaminases 26 96 1 4 0 0 0 0 0 0 
Bilirubin 27 100 0 0 0 0 0 0 0 0 
Renal 16 59 10 37 1 4 0 0 0 0 
Hypomagnesaemia 5 19 8 31 8 31 2 8 3 11 
Neurotoxicity 26 96 1 4 0 0 0 0 0 0 
Ototoxicity 26 96 1 4 0 0 0 0 0 0 1460 C Huisman et al 
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In the present study, responses were obtained both in sensitive
(defined as relapsing more than 3 months after prior chemo-
therapy) and refractory patients. There was no clear correlation
between a response to first-line and to second-line therapy. As
reviewed elsewhere (Huisman et al, 2000), conflicting results have
been reported about the influence of response to prior platinum-
containing chemotherapy. In the current study, 5 out of 9 respon-
ders had received previous platinum-containing chemotherapy.
One of them was progressive on a first-line platinum-containing
regimen, whereas the duration of response to first-line therapy of
the 4 other patients ranged from 3 to 10 months. Moreover, neither
neurotoxicity nor nephrotoxicity were severe in the subgroup of
patients, which emphasizes the feasibility to administer platinum-
containing chemotherapy to patients who were pretreated with
platinum. In our phase II study severe myelosuppression was
frequent, with 6 cases of febrile neutropenia and 2 treatment-
related deaths, limiting its use in the second-line setting to a
selected group of patients with a good performance status. 15% of
courses were postponed due to thrombocytopenia. It is important
to consider the effect of frequent dose delay due to insufficient
bone marrow recovery on the dose-intensity intended. In the phase
II part of our study, the relative dose intensities of cisplatin and
epirubicin were 0.93 and 0.92, respectively. In general, the throm-
bocytopenia was readily reversible and no serious haemorrhagic
events occurred. 
Non-haematological toxicity was generally mild. Renal toxicity
was not more evident in patients who had received prior cisplatin-
containing chemotherapy, probably due to the moderate dose of
platinum used in this schedule. No clinical manifestations of
congestive heart failure were observed during treatment or follow-
up phase of the phase II study. Since it has been demonstrated that a
cumulative dose of 1000 mg m–2 epirubicin is infrequently associ-
ated with cardiac toxicity (Smit et al, 1992), we do not recommend
routine evaluation of left ventricular function for this schedule. 
Whereas G-CSF support (300 – 480 µ g day–1) was valuable at
an epirubicin dose of 135 µ gm –2 in the current study, others have
concluded that GM-CSF 250 µ gm –1 did not have a myeloprotec-
tive effect when epirubicin was increased beyond 120 mg m–2
(Rossel et al, 1994). However, a different protocol of GM-CSF
administration was applied in this study of small-cell lung cancer
patients, since GM-CSF was administered only to those patients
who developed febrile neutropenia in a previous cycle. Moreover,
absence of myeloprotection provided by GM-CSF was most
pronounced at epirubicin doses of 150 mg m–2. At the 130 mg m–2
epirubicin dose effective myeloprotection was achieved in 2 out of
3 patients, whereas the patient in whom GM-CSF support was not
effective had already received 5 previous cycles of chemotherapy.
The authors do not describe the effect of GM-CSF in 3 patients
who encountered febrile neutropenia in their second, fifth and
eighth cycle at an epirubicin dose of 140 mg m–2. Finally, at an
epirubicin dose of 150 mg m–2 myelosuppression was clearly
severe and could not be prevented by GM-CSF administration. 
The second-line activity of accelerated cisplatin and high-dose
epirubicin with G-CSF support generates interest in evaluating 
this schedule as a first-line regimen for advanced NSCLC.
Haematological toxicity was severe but manageable and may well
be better tolerated in untreated patients. Moreover, especially for
patients receiving combined modality treatment, a chemotherapy
schedule that can be completed within a short time period is an
attractive treatment option. Martoni et al reported interesting
results from a trial with a comparable but not accelerated regimen
in the first-line setting (Martoni et al, 1992). They treated 37
patients with advanced NSCLC with cisplatin (60 mg m–2) and
epirubicin (120 mg m– 2) on day 1 every 28 days and observed a
54% response rate with median response duration of 10 months
and median survival of 9 months. They attributed their high
response rate to doubling of the epirubicin dose as compared to an
earlier study that achieved an 18% response rate with epirubicin 60
mg m–2 and cisplatin 50 mg m–2 (Lelli et al, 1986). Results from a
consecutive multicentre randomized clinical trial confirmed that
cisplatin plus high-dose epirubicin is an active first-line regimen in
stage III A–IV NSCLC, with a 32% response rate and a 42% 
1-year survival (Martoni et al, 1998). We feel the combination of
these drugs accelerated by G-CSF should be investigated further
for its role as neoadjuvant chemotherapy. Although epirubicin is
less cardiotoxic than doxorubicin, patients receiving subsequent
radiotherapy should be monitored carefully. 
In conclusion, accelerated cisplatin and high-dose epirubicin
with G-CSF support is feasible and promising in relapsed NSCLC.
Myelosuppression limits its use in the second-line setting to a
selected group of patients with a good performance status. Since
the activity of this regimen is encouraging, it is probably best
studied in untreated patients. 
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